ACCESSWIRE
11 Jan 2021, 20:43 GMT+10
LONDON, UK / ACCESSWIRE / January 11, 2021 / InMed Pharmaceuticals has now announced top-line results from both the 755-101-HV and 755-102-HV Phase I trials. Trial 755-101-HV was conducted in 22 healthy adult volunteers with intact skin, while 755-102-HV was conducted in eight healthy volunteers with small wounds. Both trials indicated that INM-755 was safe and well tolerated. There were no systemic or serious adverse effects, nor were there any adverse event-related withdrawals. Additionally, systemic drug concentrations were very low, which is desirable in a topical therapy.
We have adjusted our valuation to US$233m (C$296m) or US$33.34 (C$42.35) per basic share from C$256m or C$1.49 per basic share. The total valuation rose due to increasing the probability of success for INM-755 to 10% from 7.5% following the positive Phase I data, rolling forward our NPVs and higher net cash following a Nasdaq offering. The per-share value increased following a one-for-33 share consolidation completed on 30 June.
Click here to view the full report.
Subscribe to Edison's content to receive reports by email.
All reports published by Edison are free-to-access and available on the website.
About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information please contact Edison:
Maxim Jacobs, +1 646 653 7027
Nathaniel Calloway, +1 646 653 7036
healthcare@edisongroup.com
Learn more at www.edisongroup.com and connect with Edison on:
LinkedIn https://www.linkedin.com/company/edison-group-
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv
SOURCE: Edison Investment Research Limited
Get a daily dose of Miami Mirror news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Miami Mirror.
More InformationThe massive campaign organized by India's farmers against laws to deregulate the agricultural sector has entered its ninth week. The ...
Dutch airline KLM is to lay off up to another 1,000 people, following the 5,000 job losses of last year.Like ...
ALBUQUERQUE, New Mexico - Nearly 60 percent of residents rate Albuquerque's quality of life as excellent or good, according to ...
NEW YORK, New York - U.S. industrial stocks closed lower on Friday as fears of prolonged lockdowns due to the ...
PARIS, France - The International Energy Agency (IEA) reduced its 2021 global oil forecast this week as fresh coronavirus lockdowns ...
SYDNEY, NSW, Australia - Stocks in Asia were sold off on Friday.All the major indices lost ground, while the rout ...
PanARMENIAN.Net - There is some evidence that a new coronavirus variant first identified in southeast England carries a higher risk ...
AMSTERDAM, Netherlands - A Canadian man, one of the world's most wanted fugitives, has been arrested by the Central Unit ...
LOS ANGELES, California (ANI/Big News Network) - American award-winning TV and radio host Larry King, who became a household name ...
PanARMENIAN.Net - Hong Kong's government declared its first lockdown on Saturday, ordering thousands of people to stay in their homes ...
WASHINGTON - Seven Democratic senators asked the Senate Ethics Committee on Thursday to investigate the actions of Republican Senators Ted ...
While Joe Biden's Presidency gives people a chance to rebuild, it also faces the bitterness and opposition of Trump's ever-loyal ...